Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $61.9 million.

  • Allogene Therapeutics' Change in Acquisitions & Divestments fell 4361.44% to $61.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.4 million, marking a year-over-year decrease of 4120.13%. This contributed to the annual value of $432.5 million for FY2024, which is 2765.96% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Change in Acquisitions & Divestments is $61.9 million, which was down 4361.44% from $53.8 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Change in Acquisitions & Divestments registered a high of $268.2 million during Q1 2021, and its lowest value of $53.8 million during Q2 2025.
  • Its 5-year average for Change in Acquisitions & Divestments is $120.5 million, with a median of $109.8 million in 2024.
  • Per our database at Business Quant, Allogene Therapeutics' Change in Acquisitions & Divestments surged by 12305.57% in 2021 and then plummeted by 7439.69% in 2022.
  • Over the past 5 years, Allogene Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $82.5 million in 2021, then grew by 20.04% to $99.1 million in 2022, then surged by 37.61% to $136.3 million in 2023, then dropped by 25.07% to $102.2 million in 2024, then plummeted by 39.4% to $61.9 million in 2025.
  • Its last three reported values are $61.9 million in Q3 2025, $53.8 million for Q2 2025, and $56.5 million during Q1 2025.